DNA health test: your genetic blueprint.

A clinical DNA health test screens medically important genes for inherited variants that can influence disease risk, how you respond to certain medications (pharmacogenomics), and traits relevant to prevention. Genetics is one input among many. It informs, but does not determine, your health.

Why DNA testing matters

Certain single-gene variants meaningfully raise the risk of conditions such as familial hypercholesterolaemia and hereditary cancers, and can guide earlier screening, prevention and family testing. Pharmacogenomic variants can also predict how you metabolise some medications. Results are most useful when they change what you and your doctor actually do.

What the clinical evidence shows

• ACMG/AMP variant classification (Richards et al. Genetics in Medicine 2015): the international standard for classifying genetic variants from pathogenic to benign.
• CPIC guidelines: peer-reviewed, evidence-based guidance translating pharmacogenomic results into prescribing decisions.
• Polygenic risk scores (Khera et al. Nature Genetics 2018): demonstrated that combining many common variants can identify people at substantially elevated risk for common diseases.

Evidence-based reference ranges

Clinical DNA results are reported as variant classifications rather than a numeric range:

Clinical interpretation

• Genetic risk is probabilistic, not deterministic. A variant raises or lowers risk, it does not guarantee an outcome.
• Findings can have implications for blood relatives, so results are provided with genetic counselling.
• A variant of uncertain significance is common and usually does not warrant action, but may be re-classified over time.

How this works at HodieLabs

DNA health testing is available as an add-on to any HodieLabs membership, delivered through an accredited genomics laboratory and interpreted with doctor guidance and counselling at our Melbourne Preventative Health & Longevity Clinic.

References

1. Richards S, et al. Standards and guidelines for the interpretation of sequence variants (ACMG/AMP). Genet Med. 2015;17:405–424.
2. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium. Clin Pharmacol Ther. 2011;89:464–467.
3. Khera AV, et al. Genome-wide polygenic scores for common diseases. Nat Genet. 2018;50:1219–1224.

This page is general information from the HodieLabs Evidence-Based Clinical Library, not medical advice. Speak with your GP about what testing and care is appropriate for you.